Dr. Foluso Bisi Ademuyiwa, MD, MPH, MSCI
Oncologist | Medical Oncology
4921 PARKVIEW PL SAINT LOUIS MO, 63110About
Foluso Bisi Ademuyiwa, MD, MPH, MSCI is a Medical Oncologist and Associate Professor of Medicine, Division of Oncology, Section of Breast Oncology at Washington University School of Medicine. Her clinical expertise is in breast cancer and medical oncology. In 1999, she earned her medical degree from the University of Ibadan in Ibadan, Nigeria. From there, she earned her MPH in 2001 at Johns Hopkins University, Baltimore followed by her MSCI in 2016 from Washington University, St. Louis.
Education and Training
University of Ibadan, Ibadan, Nigeria MD 1999
Johns Hopkins University, Baltimore MPH 2001
Washington University, St. Louis MSCI 2016
University College Hospital, Ibadan, Nigeria Internship 2000
Bridgeport Hospital/Yale New Haven Health Residency 2006
Indiana University, Indianapolis Fellowship 2009
Board Certification
Medical Oncology
Internal MedicineAmerican Board of Internal MedicineABIM- Medical Oncology
PediatricsAmerican Board of PediatricsABP
Provider Details
Expert Publications
Data provided by the National Library of Medicine- Racial differences in genetic factors associated with breast cancer.
- Cetuximab in non-small cell lung cancer.
- A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.
- Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy.
- Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type.
- An 81-year-old patient with distant metastasis of invasive lobular carcinoma occurring 41 years after mastectomy.
- Time-trends in survival in young women with breast cancer in a SEER population-based study.
- Reply to Differences in 25-hydroxyvitamin D concentrations may explain most of the black-white breast cancer disparities noted in young women.
- Managing breast cancer in younger women: challenges and solutions.
Clinical Trials
- Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
- Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
- Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
- Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
- Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
- Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
- High Dose Vitamin D vs Standard Dose Vitamin D Study
- Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- A Safety Study of SGN-LIV1A in Breast Cancer Patients
Awards
- Cynthia and Robert Lawrence Scholarship, Johns Hopkins School of Publi 2001
- ECOG Young Investigator Symposium Awardee - 2008 2001
Dr. Foluso Bisi Ademuyiwa, MD, MPH, MSCI's Practice location
Dr. Foluso Bisi Ademuyiwa, MD, MPH, MSCI's reviews
Write ReviewPatient Experience with Dr. Ademuyiwa
Recommended Articles
- Why Clinical Trials Are Essential for Advancement in Ovarian Cancer Treatment
Women who have ovarian cancer need to understand that the best hope for improved screening methods and more effective treatments lies within their participation in clinical trials. Research is the cornerstone of improved medical advances, but work needs to be done at every level and for every stage...
- Are There Routine Checks for Ovarian Cancer?
Ovarian cancer is the most common cause of death among gynecologic types of cancer. The most common risk factors for ovarian cancer are:...
- What Primary Care Providers Need to Know About Ovarian Cancer
In the United States, there will be 22,440 women diagnosed with ovarian cancer in 2017 and over half of those cases will be fatal, according to the American Cancer Society. For women, ovarian cancer is the fifth leading cause of cancer deaths. And a woman’s risk of developing ovarian cancer in her...
- Facebook Photo Reveals Little-Known Breast Cancer Symptom
Thirty-seven-year-old Sherrie Rhodes was doing what many people do on a hot June day, going swimming. While she was putting on her bathing suit, the mother of three realized something unusual. On the outer side of her left breast, Sherrie noticed an indentation in her skin. Remembering a recent...
- What Is Nodular Melanoma?
Melanoma is a serious skin cancer which arises from pigment cells called as melanocytes. An invasive form of melanoma is called nodular melanoma. Nodular melanoma is a serious skin cancer that got its name from the word "nodule", a doctor’s term for a lump as nodular melanoma lesions are shaped...
- Radiation Therapy vs Chemotherapy
Radiation TherapyIn this method, the doctors will use gamma rays, x-rays, and charged particles that will be directed at, implanted, or introduced directly into the blood stream. In this form of treatment, you will find the three types of therapy that will all be described according to way they...
Nearby Providers
- Dr. Pankaj K. Singhal MD, MS128 Vision Park Blvd The Woodlands TX 77384
- Dr. Maureen Ross MD PHD128 Vision Park Blvd The Woodlands TX 77384
- Dr. Ellis Levine MD128 Vision Park Blvd The Woodlands TX 77384
- Dr. Saby George MD128 Vision Park Blvd The Woodlands TX 77384
- Dr. Krishna Pachipala M.D.18488 Interstate 45 S Shenandoah TX 77384
- Dr. Tracey L O'connor MD128 Vision Park Blvd The Woodlands TX 77384